New yeast-based particles may treat gut disease and mental health symptoms
Researchers developed nanozyme-exoskeletonized yeast-derived polysaccharides to target inflammation and anxiety in inflammatory bowel disease.
Scientists developed nanozyme-exoskeletonized yeast-derived polysaccharides, called NZEP, to treat inflammatory bowel disease. This condition often includes anxiety and depression. NZEP TA-Ce is a version with the highest degree of nanozyme-exoskeletonization.
The team used an insect sclerotization-inspired strategy to integrate nanozymes with yeast-derived polysaccharides. Nanozymes are integrated with polysaccharides to create NZEP. Sclerotization is a strategy inspired by insects.
NZEP TA-Ce can inhibit MAPK and NF-κB-mediated inflammatory signaling pathways. This action helps disrupt the inflammatory vicious cycle. Oral administration in mice allows the particles to accumulate in inflamed colonic regions.
The treatment reverses intestinal inflammation homeostasis imbalance and promotes intestinal barrier repair. It also reverses gut microbiota dysbiosis and optimizes microbial metabolites. This process may alleviate anxiety and depressive symptoms associated with inflammatory bowel disease.
This study provides a safe and promising therapeutic strategy. It aims to manage inflammatory bowel disease and its associated psychological comorbidities.
Key facts
- NZEP TA-Ce inhibits MAPK and NF-κB-mediated inflammatory signaling pathways.
- Oral NZEP TA-Ce helps repair the intestinal barrier and reverses gut microbiota dysbiosis.
- The treatment may alleviate anxiety and depressive symptoms in mice with inflammatory bowel disease.